Organic Active Ingredients TRIZ Cases

A dual mGluR5 and HDAC6 antagonist balances dopamine and glutamate pathways to treat movement disorders with fewer L-DOPA dyskinesia side effects.

Reduced-protein hydrolysed formula with HMOs and limited MCTs helps infants with CMPA lower infection risk while supporting growth.

Hydrophilic indole ER antagonists improve oral exposure, tissue distribution, and mutant receptor targeting in AI-resistant breast cancer.

A cholesterol-linked complementary strand helps an antisense nucleic acid complex cross the BBB and regulate target transcriptional products in the CNS.

An acidic high-strength pregabalin oral liquid improves solubility, stability, and palatability for rapid anxiety relief in cats.

A fixed 42 mg lumateperone dose with food treats schizophrenia in mild hepatic impairment without titration while limiting adverse effects.

Cycloalkylammonium benzoate salts improve water solubility and solid-state stability, enabling intravenous ischemic stroke treatment.

Neutral-lipid liposomal aminoglycosides are nebulized into fine aerosols to preserve drug loading and improve lung delivery through mucus and biofilms.

Novel substituted tricyclic compounds inhibit IDO to counter immunosuppression, restore T-cell activity, and address tumor resistance.

Small-molecule fused imidazole derivatives improve oral GLP-1 receptor activation while addressing short peptide action in diabetes treatment.

Specific excipient ratios and non-wet granulation stabilize keto-amide anti-SARS-CoV-2 tablets while enabling rapid dissolution.

Substituted piperidine compounds activate OX2R to improve alertness and reduce narcolepsy symptoms while supporting target protein capture.

Micronizing prasugrel with water-insoluble hydrophilic excipients improves dissolution while preserving chemical and polymorphic stability.

Non-nucleotide STING agonists activate interferon signaling to boost tumor regression while simplifying combination therapy with checkpoint drugs.

Low detergent-to-protein ratios plus higher aluminum stabilize rLP2086 Subfamily A and B antigens while preserving potency and limiting aggregation.

Retinal AAV-delivered DREADDs use natural ganglion cell pathways to target the locus coeruleus without direct brain injection.

High-temperature racemization and base treatment recover atropisomer from DBTA tartrate streams, cutting waste while preserving stereochemical purity.

Palladium-catalyzed coupling with controlled base use enables large-scale ROCK inhibitor synthesis with fewer by-products and shorter reaction time.

Selective pyrazolyl derivatives covalently bind cysteine 12 on mutant RAS proteins, blocking signaling in KRAS, HRAS, and NRAS G12C cancers.

An intramolecular disulfide bridge helps epidithiodioxopiperazine derivatives selectively inhibit tumor growth and metastasis in solid cancers.

Broad KIT and PDGFRA mutation coverage helps ripretinib treat resistant advanced GIST while extending progression-free survival.

A rapid-release DPP1 inhibitor tablet uses optimized particle size and excipients to improve dissolution, dosage consistency, and bioavailability.

A dual angiotensin and endothelin receptor antagonist lowers UP/C ratio and reduces proteinuria in Alport syndrome.

EC-8042 evicts residual SWI/SNF from chromatin, amplifies H3K27me3, and drives apoptosis in SMARCB1-mutant tumors.

Medium-chain triglycerides replace water to keep nitrazepam oral solution stable against hydrolysis and oxidation without refrigeration.

An effervescent quinolone formulation improves oral absorption to reduce GI side effects, residual gut exposure, and resistance pressure.

By silencing AGT mRNA with dsRNA, this case shows a targeted way to lower angiotensinogen and reduce polypharmacy in hypertension care.

A chiral acid salt resolution route isolates (−)-cibenzoline succinate at high purity and yield while avoiding costly, impurity-prone synthesis.

Selective stem-loop aptamers bind IL8 with sub-nanomolar affinity and retain binding in heparan sulphate for ocular disease inhibition.

A PLK4 inhibitor combined with Venetoclax and 5-Azacytidine improves treatment options for refractory AML and MDS, including complex karyotypes.

Cytosine-enriched, codon-optimized mRNA lowers immune receptor affinity and cytokine release while preserving protein expression for repeat dosing.

Selective phthalazine P2X3 inhibitors improve cough and asthma therapy while limiting taste side effects from P2X2/3 activity.

A sublingual SERM and pregnenolone composition raises testosterone while maintaining LH and FSH to avoid TRT-related fertility loss.

GalNAc-conjugated HSD17B13 RNAi agents enable selective hepatocyte delivery and gene silencing for NAFLD, NASH, fibrosis, and cirrhosis.

Base-pair-mimicking nanomaterials self-assemble into nanotubes that deliver therapeutic agents with lower toxicity and better biocompatibility.

Selective N-substituted indole Nav1.7 inhibitors address inadequate pain and itch treatment while avoiding reliance on opioid-based therapy.

Topical sulfur donors and alkalinizing agents raise follicular sulfotransferase activity to improve minoxidil activation in alopecia treatment.

An euglobulin-plasmin substrate assay measures defibrotide biological activity with better precision and reproducibility across variable batches.

Engineered anti-PTK7 antibody variants improve ADC stability, half-life, conjugation efficiency, and therapeutic targeting.

Combining a SERM with pregnenolone raises testosterone while maintaining LH and FSH, helping preserve endogenous production during TRT.

A 2′-fucosyllactose and difucosyllactose mix reduces infant abdominal pain by restoring gut-brain pain signaling without drug side effects.

A thixotropic gel centrifugation tube separates thrombin serum and PRP with consistent yield and viability for immediate wound-healing use.

Structural variation of pyrroloimidazole orexin-2 agonists improves narcolepsy efficacy while balancing pharmacokinetics and side effects.

Covalent E6-binding compounds disrupt the E6-E6AP complex, restore p53, and treat established HPV lesions and cancers.

A Vi/Vc zone inhibitor composition relieves ocular discomfort and improves corneal epithelial disorders in dry eye treatment.

Tricyclic FGFR inhibitors use tuned substituent structures to target aberrant FGFR activity and address tumor resistance in cancer treatment.

2,3-Dihydrofuro[3,2-c]pyridine derivatives improve ROCK-I/II selectivity and pharmacological properties for asthma, COPD, IPF, and PAH.

Enzyme-catalyzed fermentation with yam-derived polyphenol oxidase and laccase boosts theaflavin mono- and digallates in black tea extract.

Compounds targeting c-abl and LRRK2 address protein misfolding and aggregation to help slow neurodegeneration progression.

A modified CBD analogue improves anticonvulsant activity by raising seizure threshold while targeting stronger cannabinoid receptor binding.